Daré targets DARE to PLAY launch in December 2025 as dual path strategy accelerates
Source: SeekingAlpha
2025-11-13 19:42:19 ET
More on Dare Bioscience
- Daré Bioscience, Inc. (DARE) Q3 2025 Earnings Call Transcript
- Dare Bioscience Q3 2025 Earnings Preview
- Seeking Alpha’s Quant Rating on Dare Bioscience
- Historical earnings data for Dare Bioscience
- Financial information for Dare Bioscience
Read the full article on Seeking Alpha
For further details see:
Daré targets DARE to PLAY launch in December 2025 as dual path strategy accelerates
Dare Bioscience Inc.
NASDAQ: DARE
DARE Trading
0.66% G/L:
$1.53 Last:
13,017 Volume:
$1.54 Open:
DARE Latest News
February 23, 2026 08:00:00 am
Daré Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer
February 11, 2026 08:00:00 am
Telehealth Now Available for DARE to PLAY(TM) Sildenafil Cream: First Evidence-Based Topical Arousal Cream for Women
DARE Stock Data
$24,148,797
13,603,346
0.17%
11
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
